CN116615441A - 多功能及多价白介素-TGF-β受体融合多肽 - Google Patents

多功能及多价白介素-TGF-β受体融合多肽 Download PDF

Info

Publication number
CN116615441A
CN116615441A CN202180083946.7A CN202180083946A CN116615441A CN 116615441 A CN116615441 A CN 116615441A CN 202180083946 A CN202180083946 A CN 202180083946A CN 116615441 A CN116615441 A CN 116615441A
Authority
CN
China
Prior art keywords
polypeptide
leu
lys
ser
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180083946.7A
Other languages
English (en)
Chinese (zh)
Inventor
C·A·佩纳富尔特迪亚兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kula Therapy Co ltd
Original Assignee
Kula Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kula Therapy Co ltd filed Critical Kula Therapy Co ltd
Priority claimed from PCT/US2021/055646 external-priority patent/WO2022086988A1/en
Publication of CN116615441A publication Critical patent/CN116615441A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN202180083946.7A 2020-10-20 2021-10-19 多功能及多价白介素-TGF-β受体融合多肽 Pending CN116615441A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063094277P 2020-10-20 2020-10-20
US63/094,277 2020-10-20
PCT/US2021/055646 WO2022086988A1 (en) 2020-10-20 2021-10-19 Multi-functional and multi-valent interleukin-tgf-beta receptor fusion polypeptides

Publications (1)

Publication Number Publication Date
CN116615441A true CN116615441A (zh) 2023-08-18

Family

ID=81257992

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180083946.7A Pending CN116615441A (zh) 2020-10-20 2021-10-19 多功能及多价白介素-TGF-β受体融合多肽

Country Status (8)

Country Link
US (2) US11407814B2 (https=)
EP (1) EP4232466A4 (https=)
JP (1) JP2023546298A (https=)
KR (1) KR20230117341A (https=)
CN (1) CN116615441A (https=)
AU (1) AU2021367306A1 (https=)
CA (1) CA3198822A1 (https=)
IL (1) IL302269A (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230117341A (ko) 2020-10-20 2023-08-08 큐라 테라퓨틱스, 인크. 다기능성 및 다가 인터류킨-tgf-베타 수용체 융합 폴리펩티드
CN117120075A (zh) 2021-02-17 2023-11-24 库拉治疗股份有限公司 抗病原体白细胞介素-TGF-β受体融合多肽

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2449753T3 (es) 2007-03-19 2014-03-21 National Research Council Of Canada Proteínas de fusión que comprenden dos dominios de unión tgf-beta
WO2009152610A1 (en) 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
EP3307783B1 (en) * 2015-06-10 2021-01-06 Emory University Compositions and conjugates comprising an interleukin and polypeptides that specifically bind tgf-beta
US20200231652A1 (en) * 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
US11168138B2 (en) * 2018-03-26 2021-11-09 Altor Bioscience, Llc Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
CN120365435A (zh) 2018-08-30 2025-07-25 免疫生物公司 单链嵌合多肽和多链嵌合多肽以及其用途
US20210061871A1 (en) 2019-08-29 2021-03-04 Nantbio, Inc. Modified N-810 and Methods Therefor
KR102402276B1 (ko) 2019-11-15 2022-05-26 주식회사 제넥신 변형된 인터루킨-7 및 tgf 베타 수용체 ii를 포함하는 융합단백질 및 이의 용도
TW202233661A (zh) 2020-10-20 2022-09-01 美商克拉治療股份有限公司 多功能及多價介白素-TGF-β受體融合多肽
KR20230117341A (ko) 2020-10-20 2023-08-08 큐라 테라퓨틱스, 인크. 다기능성 및 다가 인터류킨-tgf-베타 수용체 융합 폴리펩티드
CN117120075A (zh) * 2021-02-17 2023-11-24 库拉治疗股份有限公司 抗病原体白细胞介素-TGF-β受体融合多肽

Also Published As

Publication number Publication date
AU2021367306A1 (en) 2023-06-01
CA3198822A1 (en) 2022-04-28
EP4232466A4 (en) 2024-11-06
KR20230117341A (ko) 2023-08-08
EP4232466A1 (en) 2023-08-30
AU2021367306A9 (en) 2024-10-10
US12258383B2 (en) 2025-03-25
US20230023954A1 (en) 2023-01-26
IL302269A (en) 2023-06-01
JP2023546298A (ja) 2023-11-01
US11407814B2 (en) 2022-08-09
US20220127332A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
CN110461871B (zh) 白蛋白结合结构域融合蛋白
US7947265B2 (en) Fusion proteins and methods for modulation of immune response
JP2021073260A (ja) 血管漏出症候群の発生を抑制するサイトカイン治療
WO2019196815A1 (zh) 一种人白介素2和抗人上皮细胞黏附分子单链抗体融合蛋白及其应用
AU2017249694A1 (en) Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (CAR)-T cell
KR20220092523A (ko) 변이체 인터루킨-2 (vIL-2) 폴리펩타이드를 코딩하는 종양용해성 바이러스 벡터
US12258383B2 (en) Multi-functional and multi-valent interleukin-TGF-beta receptor fusion polypeptides
AU2020242520A1 (en) Method for the expansion and differentiation of T lymphocytes and NK cells in adoptive transfer therapies
US20240360191A1 (en) Targeted IL-12 Treatments and Methods to Stimulate haNK and NK92mi Cells
US12329803B2 (en) Method of reducing or treating fibrosis by administering an interleukin-2/TGF-beta receptor fusion polypeptide
TW202233661A (zh) 多功能及多價介白素-TGF-β受體融合多肽
EP1401377A2 (en) Methods for treating cancer
KR20240043797A (ko) 암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합
JP4989850B2 (ja) ＴＧＦ−βの遮断により腫瘍再発を防ぐ方法
US20240352088A1 (en) Chimeric cytokine receptor
WO2026030625A1 (en) Therapeutic compositions and methods for treating cancer
WO2026003203A1 (en) Combination of an immunocytokine comprising targeted il2 and a jak inhibitor
CN121693512A (zh) 包括用于治疗癌症的工程化il-7多肽和工程化il-12多肽的方法和组合物
HK40114315A (zh) 包含抗cd73抗体和il-2的融合蛋白及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination